Literature DB >> 26930513

Younger age at initiation of the human papillomavirus (HPV) vaccination series is associated with higher rates of on-time completion.

Jennifer L St Sauver1, Lila J Finney Rutten2, Jon O Ebbert3, Debra J Jacobson4, Michaela E McGree4, Robert M Jacobson5.   

Abstract

Vaccination rates for human papillomavirus (HPV) have remained disappointingly low. It is critical to identify methods to increase on-time vaccine series completion rates (before 13 or 15years). To determine whether younger age (9 to 10years of age) at HPV vaccine series initiation was associated with improved on-time completion rates compared to initiation at 11 to 12years, we examined the prevalence of on-time HPV vaccine series completion rates from August 2006 through December 2012 in a large, population-based cohort of children and adolescents (aged 9.5 to 27years) residing in Olmsted County, MN on December 31, 2012 (n=36,223). We compared age at vaccine initiation between individuals who successfully completed both 2 and 3 doses of the vaccination series on-time (before age 13.5 or 15.0years) using multivariate logistic regression. On-time completion of both 2 and 3 doses of the vaccine series by age 13.5 or 15.0years was significantly associated with initiation at 9 to 10years as compared to 11 to 12years after adjusting for sex, race, insurance status, frequent health care visits, and year of first vaccination (all p<.01). Interventions focused on beginning the vaccination series at 9 to 10years of age may result in higher rates of timely series completion.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Immunization; Immunization programs; Papillomavirus vaccines, vaccination; Patient acceptance of health care; Patient compliance

Mesh:

Substances:

Year:  2016        PMID: 26930513      PMCID: PMC4969174          DOI: 10.1016/j.ypmed.2016.02.039

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  29 in total

1.  FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-05-28       Impact factor: 17.586

2.  Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system.

Authors:  Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Joshua J Pankratz; Scott M Brue; Walter A Rocca
Journal:  Int J Epidemiol       Date:  2012-11-18       Impact factor: 7.196

3.  Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006.

Authors:  Susan Hariri; Elizabeth R Unger; Maya Sternberg; Eileen F Dunne; David Swan; Sonya Patel; Lauri E Markowitz
Journal:  J Infect Dis       Date:  2011-08-15       Impact factor: 5.226

4.  A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.

Authors:  Elmar A Joura; Anna R Giuliano; Ole-Erik Iversen; Celine Bouchard; Constance Mao; Jesper Mehlsen; Edson D Moreira; Yuen Ngan; Lone Kjeld Petersen; Eduardo Lazcano-Ponce; Punnee Pitisuttithum; Jaime Alberto Restrepo; Gavin Stuart; Linn Woelber; Yuh Cheng Yang; Jack Cuzick; Suzanne M Garland; Warner Huh; Susanne K Kjaer; Oliver M Bautista; Ivan S F Chan; Joshua Chen; Richard Gesser; Erin Moeller; Michael Ritter; Scott Vuocolo; Alain Luxembourg
Journal:  N Engl J Med       Date:  2015-02-19       Impact factor: 91.245

5.  Completion of the human papillomavirus vaccine series among insured females between 2006 and 2009.

Authors:  Jacqueline M Hirth; Alai Tan; Gregg S Wilkinson; Abbey B Berenson
Journal:  Cancer       Date:  2012-04-27       Impact factor: 6.860

6.  Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester epidemiology project.

Authors:  Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Walter A Rocca
Journal:  Am J Epidemiol       Date:  2011-03-23       Impact factor: 4.897

7.  Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.

Authors:  Stan L Block; Terry Nolan; Carlos Sattler; Eliav Barr; Katherine E D Giacoletti; Colin D Marchant; Xavier Castellsagué; Steven A Rusche; Suzanne Lukac; Janine T Bryan; Paul F Cavanaugh; Keith S Reisinger
Journal:  Pediatrics       Date:  2006-11       Impact factor: 7.124

8.  Against which human papillomavirus types shall we vaccinate and screen? The international perspective.

Authors:  Nubia Muñoz; F Xavier Bosch; Xavier Castellsagué; Mireia Díaz; Silvia de Sanjose; Doudja Hammouda; Keerti V Shah; Chris J L M Meijer
Journal:  Int J Cancer       Date:  2004-08-20       Impact factor: 7.396

9.  Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.

Authors:  Keith S Reisinger; Stan L Block; Eduardo Lazcano-Ponce; Rudiwilai Samakoses; Mark T Esser; Joanne Erick; Derek Puchalski; Katherine E D Giacoletti; Heather L Sings; Suzanne Lukac; Frances B Alvarez; Eliav Barr
Journal:  Pediatr Infect Dis J       Date:  2007-03       Impact factor: 2.129

10.  National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years--United States, 2014.

Authors:  Sarah Reagan-Steiner; David Yankey; Jenny Jeyarajah; Laurie D Elam-Evans; James A Singleton; C Robinette Curtis; Jessica MacNeil; Lauri E Markowitz; Shannon Stokley
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-07-31       Impact factor: 17.586

View more
  10 in total

1.  A Population-Based Study of Sociodemographic and Geographic Variation in HPV Vaccination.

Authors:  Lila J Finney Rutten; Patrick M Wilson; Debra J Jacobson; Amenah A Agunwamba; Carmen Radecki Breitkopf; Robert M Jacobson; Jennifer L St Sauver
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-02-14       Impact factor: 4.254

2.  Human papilloma virus vaccination and cervical cancer screening coverage in managed care plans - United States, 2018.

Authors:  Thomas B Richards; Megan C Lindley; Sepheen C Byron; Mona Saraiya
Journal:  Prev Med       Date:  2022-03-10       Impact factor: 4.018

3.  Recommending Human Papillomavirus Vaccination at Age 9: A National Survey of Primary Care Professionals.

Authors:  Wei Yi Kong; Qian Huang; Peyton Thompson; Brigid K Grabert; Noel T Brewer; Melissa B Gilkey
Journal:  Acad Pediatr       Date:  2022-01-23       Impact factor: 2.993

4.  Social determinants of human papillomavirus vaccine series completion among U.S. adolescents: A mixed-methods study.

Authors:  Lisa N Mansfield; Richard J Chung; Susan G Silva; Elizabeth I Merwin; Rosa M Gonzalez-Guarda
Journal:  SSM Popul Health       Date:  2022-03-26

5.  Predictors of Human Papillomavirus Vaccine Follow-Through Among Privately Insured US Patients.

Authors:  Jennifer C Spencer; Noel T Brewer; Justin G Trogdon; Stephanie B Wheeler; Stacie B Dusetzina
Journal:  Am J Public Health       Date:  2018-05-17       Impact factor: 9.308

6.  Operationalizing outcome measures of human papillomavirus vaccination among adolescents.

Authors:  C Odoh; M Sanderson; E A Williams; P C Hull
Journal:  Public Health       Date:  2018-03-30       Impact factor: 2.427

7.  Trends in HPV Vaccination Initiation and Completion Within Ages 9-12 Years: 2008-2018.

Authors:  Onyema Greg Chido-Amajuoyi; Rajesh Talluri; Chizoba Wonodi; Sanjay Shete
Journal:  Pediatrics       Date:  2021-05-03       Impact factor: 9.703

8.  Missed opportunities for concomitant HPV vaccination among childhood cancer survivors.

Authors:  Joemy M Ramsay; Heydon K Kaddas; Judy Y Ou; Deanna Kepka; Anne C Kirchhoff
Journal:  Cancer Med       Date:  2022-01-14       Impact factor: 4.452

9.  Challenges to Adolescent HPV Vaccination and Implementation of Evidence-Based Interventions to Promote Vaccine Uptake During the COVID-19 Pandemic: "HPV Is Probably Not at the Top of Our List".

Authors:  Grace Ryan; Paul A Gilbert; Sato Ashida; Mary E Charlton; Aaron Scherer; Natoshia M Askelson
Journal:  Prev Chronic Dis       Date:  2022-03-31       Impact factor: 2.830

10.  Adherence to the Recommended HPV Vaccine Dosing Schedule among Adolescents Aged 13 to 17 Years: Findings from the National Immunization Survey-Teen, 2019-2020.

Authors:  Chinenye Lynette Ejezie; Ikponmwosa Osaghae; Sylvia Ayieko; Paula Cuccaro
Journal:  Vaccines (Basel)       Date:  2022-04-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.